-
Lundbeck launches new treatment for rare form of acute leukemia
MONTREAL | Health Canada has approved Trisenox (arsenic trioxide) for relapsed or refractory acute promyelocytic leukemia (APL). This was made possible by a decision from Health Canada's Therapeutic Products Directorate to remove a prior regulatory prohibition on arsenic-containing drug therapies for use in humans and by granting priority review.